Author Archives: Marisa Wexler MS

Study Supports Use of Rituximab-containing Therapies in CAD

Therapies that contain Rituximab may be effective for people with cold agglutinin disease (CAD), a study suggests. The study, “Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients,” was published in Scientific Reports. CAD is caused by cold agglutinins — a…

COVID-19 Thought To Be Cause of CAD in Woman in Case Report

A case report from Michigan suggests that coronavirus disease 2019 (COVID-19) could cause cold agglutinin disease (CAD). Results showed that appropriate treatment, including folic acid and a steroid, lowered inflammation and nearly corrected levels of blood cells. The report, “Cold agglutinin disease and autoimmune hemolytic…

FDA Gives Priority Review to Sutimlimab for Adults with CAD

The U.S. Food and Drug Administration (FDA) is giving priority review to Sanofi’s request that sutimlimab be approved to treat hemolysis in adults with cold agglutinin disease (CAD). The FDA is expected to announce its decision on or before Nov. 13, as priority review shortens the regulatory process…

Phase 3 Data Support Safety, Efficacy of Sutimlimab in Treating CAD

The investigational therapy sutimlimab prevented hemolysis, significantly increased hemoglobin, and improved the quality of life in patients with cold agglutinin disease (CAD), according to data from a Phase 3 clinical trial. The results will be presented at the Annual Meeting of the American Society of Hematology in December, in…

Study Finds Risk Factors for AIHA Following Stem Cell Transplant

Immune rejection and half-matched donors are risk factors for developing autoimmune hemolytic anemia (AIHA) following blood cancer-treating stem cell transplants, a study found. Titled “Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience,” the study was published in the…